Proteomic approaches to unravel the complexity of schizophrenia

Expert Review of Proteomics

Volumn 9, Issue 1, 2012, Pages 97-108

  Martins De Souza, Daniel ^a,c   Guest, Paul C ^a   Rahmoune, Hassan ^a   Bahn, Sabine ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Biomarker; Calcium; Diagnostic; Drug response; Energy metabolism; Oligodendrocytes; Proteome; Proteomics; Schizophrenia; Shotgun mass spectrometry

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A5; APOLIPOPROTEIN C1; ARGIPRESSIN; BETA ACTIN; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 13B; C PEPTIDE; CELL PROTEIN; CHROMOGRANIN A; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYANINE DYE; CYTOSKELETON PROTEIN; DOPAMINE RECEPTOR; FLUORESCENT DYE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; GLUTATHIONE TRANSFERASE; GLYCOLYTIC ENZYME; HYDROCORTISONE; IMMUNOGLOBULIN; INSULIN; NEUROLEPTIC AGENT; PEROXIREDOXIN; PROINSULIN; PROTEOME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRANSFERRIN;

ANALYTIC METHOD; BIPOLAR DISORDER; CONCENTRATION (PARAMETERS); DIAGNOSTIC VALUE; ELECTROSPRAY MASS SPECTROMETRY; ENERGY METABOLISM; FLUOROMETRY; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOASSAY; ISOBARIC TAG FOR RELATIVE AND ABSOLUTE CONCENTRATION; ISOELECTRIC FOCUSING; ISOTOPE CODED PROTEIN LABELING; ISOTOPE LABELING; LIVER; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MENTAL PATIENT; MICROARRAY ANALYSIS; NEUROENDOCRINE SYSTEM; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SCHIZOPHRENIA; SKIN FIBROBLAST; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; TRANSCRIPTOMICS; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; TWO DIMENSIONAL ELECTROPHORESIS;

BIOLOGICAL MARKERS; HUMANS; PROTEOMICS; SCHIZOPHRENIA;

EID: 84856624607     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.11.70     Document Type: Review

References (113)

1. Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur. Arch. Psychiatr. Clin. Neurosci. 250(6), 274-285 (2000). (Pubitemid 32002381)
2. Weickert TW, Goldberg TE, Gold JM, Bigelow LB, Egan MF, Weinberger DR. Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Arch. Gen. Psychiatr. 57(9), 907-913 (2000).
3. Wildenauer DBWD, Schwab SG. Molecular Biology of Neuropsychiatric Disorders. Springer, Heidelberg, Germany (2009).
4. Torrey EF. Surviving Schizophrenia: A Manual for Families, Patients, and Providers. Collins, NY, USA (2006).
5. Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J. Psychopharmacol. 24(Suppl. 4), S81-S90 (2010).
6. Freedman R. Schizophrenia. N. Engl. J. Med. 349(18), 1738-1749 (2003). (Pubitemid 37315012)
7. Gejman PV, Sanders AR, Kendler KS. Genetics of schizophrenia: new findings and challenges. Annu. Rev. Genom. Hum. Genet. 12, 121-144 (2011).
8. Martins de Souza D, Dias-Neto E. RNA biomarkers in schizophrenia. In: Biomarkers for Psychiatric Disorders. Turck CW (Ed.). Springer, NY, USA, 97-127 (2009).
9. Harris LW, Wayland M, Lan M et al. The cerebral microvasculature in schizophrenia: a laser capture microdissection study. PLoS One 3(12), e3964 (2008).
10. Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J. Neurosci. 22(7), 2718-2729 (2002). (Pubitemid 37465821)
11. Aston C, Jiang L, Sokolov BP. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J. Neurosci. Res. 77(6), 858-866 (2004). (Pubitemid 39187068)
12. Hakak Y, Walker JR, Li C et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl Acad. Sci. USA 98(8), 4746-4751 (2001). (Pubitemid 32295047)
13. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28(1), 53-67 (2000).
14. Vawter MP, Barrett T, Cheadle C et al. Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Res. Bull. 55(5), 641-650 (2001). (Pubitemid 32888383)
15. Tkachev D, Mimmack ML, Ryan MM et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 362(9386), 798-805 (2003). (Pubitemid 37093922)
16. Martins-De-Souza D, Dias-Neto E, Schmitt A et al. Proteome analysis of schizophrenia brain tissue. World J. Biol. Psychiatr. 11(2), 110-120 (2010).
17. Herrman H. Schizophrenia and biological determinism. Aust. NZ J. Psychiatr. 23(1), 48-52 (1989). (Pubitemid 19100325)
18. Harrison PJ. Using our brains: the findings, flaws, and future of postmortem studies of psychiatric disorders. Biol. Psychiatr. 69(2), 102-103 (2010).
19. Kleinman JE, Law AJ, Lipska BK et al. Genetic neuropathology of schizophrenia: new approaches to an old question and new uses for postmortem human brains. Biol. Psychiatr. 69(2), 140-145 (2010).
20. Huang JT, Leweke FM, Oxley D et al. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med. 3(11), e428 (2006).
21. Martins-De-Souza D, Wobrock T, Zerr I et al. Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls. World J. Biol. Psychiatr. 11(5), 719-728 (2010).
22. Huang JT, Leweke FM, Tsang TM et al. CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS One 2(1), e756 (2007).
23. Levin Y, Wang L, Schwarz E, Koethe D, Leweke FM, Bahn S. Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. Mol. Psychiatr. 15(11), 1088-1100 (2010).
24. Schwarz E, Izmailov R, Spain M et al. Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark. Insights 5, 39-47 (2010).
25. Prabakaran S, Wengenroth M, Lockstone HE, Lilley K, Leweke FM, Bahn S. 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia. J. Proteome Res. 6(1), 141-149 (2007). (Pubitemid 46173666)
26. Krishnamurthy D, Harris LW, Levin Y et al. Metabolic, hormonal and stress-related molecular changes in post-mortem pituitary glands from schizophrenia subjects. World J. Biol. Psychiatry (2011) (In press).
27. Wang L, Lockstone HE, Guest PC et al. Expression profiling of fibroblasts identifies cell cycle abnormalities in schizophrenia. J. Proteome Res. 9(1), 521-527 (2010).
28. Herberth M, Koethe D, Cheng TM et al. Impaired glycolytic response in peripheral blood mononuclear cells of first-onset antipsychotic-naive schizophrenia patients. Mol. Psychiatr. 16(8), 848-859 (2011).
29. O'Farrell PH. High resolution twodimensional electrophoresis of proteins. J. Biol. Chem. 250(10), 4007-4021 (1975).
30. Bjellqvist B, Ek K, Righetti PG et al. Isoelectric focusing in immobilized pH gradients: principle, methodology and some applications. J. Biochem. Biophys. Methods 6(4), 317-339 (1982).
31. Gorg A, Postel W, Gunther S et al. Approach to stationary two-dimensional pattern: influence of focusing time and immobiline/carrier ampholytes concentrations. Electrophoresis 9(1), 37-46 (1988).
32. Westermeier R, Postel W, Weser J, Gorg A. High-resolution two-dimensional electrophoresis with isoelectric focusing in immobilized pH gradients. J. Biochem. Biophys. Methods 8(4), 321-330 (1983).
33. Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 18(11), 2071-2077 (1997). (Pubitemid 27501267)
34. Pennington K, Dicker P, Dunn MJ, Cotter DR. Proteomic analysis reveals protein changes within layer 2 of the insular cortex in schizophrenia. Proteomics 8(23-24), 5097-5107 (2008).
35. Prabakaran S, Swatton JE, Ryan MM et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatr. 9(7), 684-697, 643 (2004). (Pubitemid 38932173)
36. Focking M, Dicker P, English JA, Schubert KO, Dunn MJ, Cotter DR. Common proteomic changes in the hippocampus in schizophrenia and bipolar disorder and particular evidence for involvement of cornu ammonis regions 2 and 3. Arch. Gen. Psychiatr. 68(5), 477-488 (2011).
37. Tumani H, Lehmensiek V, Lehnert S, Otto M, Brettschneider J. 2D DIGE of the cerebrospinal fluid proteome in neurological diseases. Expert Rev. Proteomics 7(1), 29-38 (2010).
38. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 68(5), 850-858 (1996).
39. Martins de Souza D, Oliveira BM, Castro-Dias E et al. The untiring search for the most complete proteome representation: reviewing the methods. Brief Funct. Genomic Proteomic 7(4), 312-321 (2008).
40. Link AJ, Eng J, Schieltz DM et al. Direct analysis of protein complexes using mass spectrometry. Nat. Biotechnol. 17(7), 676-682 (1999). (Pubitemid 29316146)
41. Haas W, Faherty BK, Gerber SA et al. Optimization and use of peptide mass measurement accuracy in shotgun proteomics. Mol. Cell Proteomics 5(7), 1326-1337 (2006). (Pubitemid 44103402)
42. Ong SE, Blagoev B, Kratchmarova I et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell Proteomics 1(5), 376-386 (2002).
43. Frank E, Kessler MS, Filiou MD et al. Stable isotope metabolic labeling with a novel N-enriched bacteria diet for improved proteomic analyses of mouse models for psychopathologies. PLoS One 4(11), e7821 (2009).
44. Chelius D, Bondarenko PV. Quantitative profiling of proteins in complex mixtures using liquid chromatography and mass spectrometry. J. Proteome Res. 1(4), 317-323 (2002). (Pubitemid 36395872)
45. Levin Y, Bahn S. Quantification of proteins by label-free LC-MS/MS. Methods Mol. Biol. 658, 217-231 (2010).
46. Li GZ, Vissers JP, Silva JC, Golick D, Gorenstein MV, Geromanos SJ. Database searching and accounting of multiplexed precursor and product ion spectra from the data independent analysis of simple and complex peptide mixtures. Proteomics 9(6), 1696-1719 (2009).
47. Kim YJ, Zhan P, Feild B, Ruben SM, He T. Reproducibility assessment of relative quantitation strategies for LC-MS based proteomics. Anal. Chem. 79(15), 5651-5658 (2007). (Pubitemid 47229811)
48. Nagele E, Vollmer M, Horth P, Vad C. 2D-LC/MS techniques for the identification of proteins in highly complex mixtures. Expert Rev. Proteomics 1(1), 37-46 (2004). (Pubitemid 43826427)
49. Shaw MM, Riederer BM. Sample preparation for two-dimensional gel electrophoresis. Proteomics 3(8), 1408-1417 (2003). (Pubitemid 37048065)
50. Falcon-Perez JM, Lu SC, Mato JM. Sub-proteome approach to the knowledge of liver. Proteomics Clin. Appl. 4(4), 407-415 (2010).
51. Johnston-Wilson NL, Sims CD, Hofmann JP et al. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol. Psychiatr. 5(2), 142-149 (2000). (Pubitemid 30229428)
52. Pennington K, Beasley CL, Dicker P et al. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol. Psychiatr. 13(12), 1102-1117 (2008).
53. Martins-de-Souza D, Gattaz WF, Schmitt A et al. Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J. Psychiatr. Res. 43(11), 978-986 (2009).
54. Martins-de-Souza D, Gattaz WF, Schmitt A et al. Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J. Neural Transm. 116(3), 275-289 (2009).
55. Clark D, Dedova I, Cordwell S, Matsumoto I. A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia. Mol. Psychiatr. 11(5), 459-470, 423 (2006).
56. Martins-de-Souza D, Schmitt A, Roder R et al. Sex-specific proteome differences in the anterior cingulate cortex of schizophrenia. J. Psychiatr. Res. 44(14), 989-991 (2010).
57. Sivagnanasundaram S, Crossett B, Dedova I, Cordwell S, Matsumoto I. Abnormal pathways in the genu of the corpus callosum in schizophrenia pathogenesis: a proteome study. Proteomics Clin. Appl. 1(10), 1291-1305 (2007).
58. Martins-de-Souza D, Gattaz WF, Schmitt A et al. Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatr. 9, 17 (2009).
59. Martins-de-Souza D, Maccarrone G, Wobrock T et al. Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J. Psychiatr. Res. 44(16), 1176-1189 (2010).
60. Nesvaderani M, Matsumoto I, Sivagnanasundaram S. Anterior hippocampus in schizophrenia pathogenesis: molecular evidence from a proteome study. Aust. NZ J. Psychiatr. 43(4), 310-322 (2009).
61. Huang JT, Wang L, Prabakaran S et al. Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol. Psychiatr. 13(12), 1118-1128 (2008).
62. Gur RE, Gur RC. Functional magnetic resonance imaging in schizophrenia. Dialog. Clin. Neurosci. 12(3), 333-343 (2011).
63. Martins-de-Souza D, Harris LW, Guest PC, Bahn S. The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. Antioxid. Redox. Signal. 15(7), 2067-2079 (2011).
64. Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H. Glutamatergic (N-methyl-d-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol. Pharmacol. 77(3), 317-326 (2010).
65. Jacquy J, Wilmotte J, Piraux A, Noel G. Cerebral blood flow patterns studied by rheoencephalography in schizophrenia. Neuropsychobiology 2(2-3), 94-103 (1976).
66. Tamminga CA, Thaker GK, Buchanan R et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch. Gen. Psych. 49(7), 522-530 (1992).
67. Yao JK, Reddy RD, van Kammen DP. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 15(4), 287-310 (2001). (Pubitemid 32337052)
68. Rezin GT, Amboni G, Zugno AI, Quevedo J, Streck EL. Mitochondrial dysfunction and psychiatric disorders. Neurochem. Res. 34(6), 1021-1029 (2009).
69. Martins-de-Souza D, Gattaz WF, Schmitt A et al. Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur. Arch. Psychiatr. Clin. Neurosci. 259(3), 151-163 (2009).
70. Maccarrone G, Turck CW, Martins-de-Souza D. Shotgun mass spectrometry workflow combining IEF and LC-MALDITOF/ TOF. Protein J. 29(2), 99-102 (2010).
71. Bergson C, Levenson R, Goldman-Rakic PS, Lidow MS. Dopamine receptorinteracting proteins: the Ca(2+) connection in dopamine signaling. Trends Pharmacol. Sci. 24(9), 486-492 (2003). (Pubitemid 37088174)
72. Kantrowitz JT, Javitt DC. Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. Clin. Schizophr. Relat. Psychoses 4(3), 189-200 (2010).
73. Gattaz WF, Hubner CV, Nevalainen TJ, Thuren T, Kinnunen PK. Increased serum phospholipase A2 activity in schizophrenia: a replication study. Biol. Psychiatr. 28(6), 495-501 (1990). (Pubitemid 20298440)
74. Martins-de-Souza D. Proteome and transcriptome analysis suggests oligodendrocyte dysfunction in schizophrenia. J. Psychiatr. Res. 44(3), 149-156 (2010).
75. Foong J, Maier M, Barker GJ, Brocklehurst S, Miller DH, Ron MA. In vivo investigation of white matter pathology in schizophrenia with magnetisation transfer imaging. J. Neurol. Neurosurg. Psychiatr. 68(1), 70-74 (2000). (Pubitemid 30248662)
76. Kubicki M, Park H, Westin CF et al. DTI and MTR abnormalities in schizophrenia: analysis of white matter integrity. Neuroimage 26(4), 1109-1118 (2005). (Pubitemid 40806489)
77. Du Y, Dreyfus CF. Oligodendrocytes as providers of growth factors. J. Neurosci. Res. 68(6), 647-654 (2002). (Pubitemid 34594982)
78. Martins-de-Souza D. Is the word 'biomarker' being properly used by proteomics research in neuroscience? Eur. Arch. Psychiatr. Clin. Neurosci. 260(7), 561-562 (2010).
79. Sawa A, Kamiya A. Elucidating the pathogenesis of schizophrenia. BMJ 327(7416), 632-633 (2003). (Pubitemid 37153550)
80. Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol. Psychiatr. 46(6), 729-739 (1999). (Pubitemid 29460898)
81. Csernansky JG. Neurodegeneration in schizophrenia: evidence from in vivo neuroimaging studies. Sci. World J. 7, 135-143 (2007). (Pubitemid 46219352)
82. Wojda U, Salinska E, Kuznicki J. Calcium ions in neuronal degeneration. IUBMB Life 60(9), 575-590 (2008).
83. La YJ, Wan CL, Zhu H et al. Decreased levels of apolipoprotein A-I in plasma of schizophrenic patients. J. Neural Transm. 114(5), 657-663 (2007). (Pubitemid 46664048)
84. du Bois TM, Deng C, Huang XF. Membrane phospholipid composition, alterations in neurotransmitter systems and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatr. 29(6), 878-888 (2005).
85. Guest PC, Wang L, Harris LW et al. Increased levels of circulating insulinrelated peptides in first-onset, antipsychotic naive schizophrenia patients. Mol. Psychiatr. 15(2), 118-119 (2010).
86. Walsh P, Spelman L, Sharifi N, Thakore JH. Male patients with paranoid schizophrenia have greater ACTH and cortisol secretion in response to metoclopramide-induced AVP release. Psychoneuroendocrinology 30(5), 431-437 (2005). (Pubitemid 40249809)
87. Heinrichs M, von Dawans B, Domes G. Oxytocin, vasopressin, and human social behavior. Front. Neuroendocrinol. 30(4), 548-557 (2009).
88. Clark C, Kopala L, Li DK, Hurwitz T. Regional cerebral glucose metabolism in never-medicated patients with schizophrenia. Can J. Psychiatr. 46(4), 340-345 (2001). (Pubitemid 32531566)
89. McDermott E, de Silva P. Impaired neuronal glucose uptake in pathogenesis of schizophrenia -can GLUT 1 and GLUT 3 deficits explain imaging, post-mortem and pharmacological findings? Med. Hypotheses 65(6), 1076-1081 (2005). (Pubitemid 41425892)
90. Guest PC, Schwarz E, Krishnamurthy D et al. Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 36(7), 1092-1096 (2011).
91. Walker JJ, Terry JR, Lightman SL. Origin of ultradian pulsatility in the hypothalamic-pituitary-adrenal axis. Proc. Biol. Sci. 277(1688), 1627-1633 (2010).
92. Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR. Focus on prolactin as a metabolic hormone. Trends Endocrinol. Metab. 17(3), 110-116 (2006).
93. Nilsson BM, Hultman CM, Wiesel FA. Niacin skin-flush response and electrodermal activity in patients with schizophrenia and healthy controls. Prostaglandins Leukot. Essent. Fatty Acids 74(5), 339-346 (2006).
94. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III -the final common pathway. Schizophr Bull. 35(3), 549-562 (2009).
95. Murray RD, Shalet SM. Insulin sensitivity is impaired in adults with varying degrees of GH deficiency. Clin. Endocrinol. (Oxf.).
96. Kahn RS, Davidson M, Hirschowitz J et al. Nocturnal growth hormone secretion in schizophrenic patients and healthy subjects. Psychiatr. Res. 41(2), 155-161 (1992).
97. Katsel P, Davis KL, Li C et al. Abnormal indices of cell cycle activity in schizophrenia and their potential association with oligodendrocytes. Neuropsychopharmacology 33(12), 2993-3009 (2008).
98. English JA, Dicker P, Focking M, Dunn MJ, Cotter DR. 2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease. Proteomics 9(12), 3368-3382 (2009).
99. Schwarz E, Guest PC, Rahmoune H et al. Identification of a blood-based biological signature in subjects with psychiatric disorders prior to clinical manifestation. World J. Biol. Psychiatr. doi: 10.3109/15622975.2011.599861 (2011) (Epub ahead of print).
100. Pelizzoni I, Macco R, Zacchetti D, Grohovaz F, Codazzi F. Iron and calcium in the central nervous system: a close relationship in health and sickness. Biochem. Soc. Trans. 36(Pt 6), 1309-1312 (2008).
101. Harrison-Findik DD. Gender-related variations in iron metabolism and liver diseases. World J. Hepatol. 2(8), 302-310 (2010).
102. Beasley CL, Pennington K, Behan A, Wait R, Dunn MJ, Cotter D. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: evidence for disease-associated changes. Proteomics 6(11), 3414-3425 (2006). (Pubitemid 43886157)
103. Ben-Shachar D, Laifenfeld D. Mitochondria, synaptic plasticity, and schizophrenia. Int. Rev. Neurobiol. 59, 273-296 (2004). (Pubitemid 39752419)
104. Muller N, Schwarz MJ. A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. Eur. Arch. Psychiatr. Clin. Neurosci. 258(Suppl. 2), S97-S106 (2008).
105. Brown AS. The environment and susceptibility to schizophrenia. Prog. Neurobiol. 93(1), 23-58 (2011).
106. Bahtiyar G, Weiss K, Sacerdote AS. Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone. Endocr. Pract. 13(6), 601-608 (2007).
107. Muller N, Riedel M, Schwarz MJ, Engel RR. Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur. Arch. Psychiatr. Clin. Neurosci. 255(2), 149-151 (2005). (Pubitemid 40558607)
108. Martins-de-Souza D, Guest PC, Vanattou-Saifoudine N, Wesseling H, Rahmoune H, Bahn S. The need for phosphoproteomic approaches in psychiatric research. J. Psychiatr. Res. 45(10), 1404-1406 (2011).
109. Martins-de-Souza D, Guest PC, Vanattou-Saifoudine N, Harris LW, Bahn, S. Proteomic technologies for biomarker studies in psychiatry: advances and needs. Int. Rev. Neurobiol. 101, 65-94 (2011).
110. Young JW, Zhou X, Geyer MA. Animal models of schizophrenia. Curr. Top. Behav. Neurosci. 4, 391-433 (2010).
111. Martins-de-Souza D, Lebar M, Turck CW. Proteome analyses of cultured astrocytes treated with MK-801 and clozapine: similarities with schizophrenia. Eur. Arch. Psychiatr. Clin. Neurosci. 261(3), 217-228 (2011).
112. Steiner J, Schroeter ML, Schiltz K et al. Haloperidol and clozapine decrease S100B release from glial cells. Neuroscience 167(4), 1025-1031 (2010).
113. Brennand KJ, Simone A, Jou J et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 473(7346), 221-225 (2011).